At a glance
ClinicalIndex Comparison RecordN/ACompleted· 330 enrolled
Drug / intervention
LumiraDX +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Feasibility and Reproducibility of 2 Point-of-Care Tests for SARS-Co-V-2 Antibodies (INSIGHT 017)
In Brief
An observational study evaluating LumiraDX, RightSign, and 1 other intervention for COVID-19 and SARS CoV 2 Infection. Completed, enrolled 330 participants across 1 site.
Detailed Summary
EPOC is designed to examine the feasibility of conducting two point-of-care (POC) tests the LumiraDx SARS-CoV-2 Antibody Test and the RightSign COVID-19 IgG/IgM Rapid Test for SARS-CoV-2 antibodies and compare the reproducibility of these tests to tests run at a central laboratory on specimens obtained from the same study participants at the same time.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, SARS CoV 2 Infection
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionSep 2022
TodayJul 2026
First PostedFeb 7, 2022
Enrollment StartApr 8, 2022
Primary CompletionSep 2, 2022
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.4 years ago
Interventions
LumiraDXother
Point-of-care test for SARS-CoV-2
RightSignother
Point-of-care test for SARS-CoV-2
Case Controlother
Genscript assay performed on the plasma sample